Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients

Clinical Microbiology and Infection

Volumn 20, Issue 10, 2014, Pages O687-O693

  He, D ^a,b   Guo, S ^a   Zhu, P ^a   Tao, S ^a   Li, M ^a   Huang, H ^a   Wang, J ^a   Wang, Y ^a   Ding, M ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Medical Services The 88th Hospital of the Chinese PLA   (China)

Author keywords

Chronic hepatitis B; Discontinuation; HBeAg positive; Nucleos(t)ide analogues; Relapse

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; TELBIVUDINE; VIRUS DNA; NUCLEOSIDE; NUCLEOTIDE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; RECURRENT DISEASE; TIME; TREATMENT WITHDRAWAL; VIROLOGY; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; NUCLEOSIDES; NUCLEOTIDES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84913605720     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12605     Document Type: Article

References (24)

1. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
2. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
3. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B. Gastroenterology 2002; 123: 1084-1089.
4. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627-631.
5. Kim JH, Lee JH, Park SJ et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterology 2008; 55: 578-581.
6. Liu J, Yang H-I, Lee M-H et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139: 474-482.
7. Kwon JH, Jang JW, Choi JY et al. Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment? J Med Virol 2013; 85: 34-42.
8. Liu F, Wang L, Li XY et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011; 26: 456-460.
9. Ha M, Zhang G, Diao S et al. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol 2012; 157: 285-290.
10. Ridruejo E, Marciano S, Galdame O et al. Relapse rates in chronic hepatitis B naive patients after discontinuation of antiviral therapy with entecavir. J Viral Hepat 2013; doi: 10.1111/jvh.12200.
11. He D, Guo S, Chen W et al. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. BMC Infect Dis 2013; 13: 458.
12. Chaung KT, Ha NB, Trinh HN et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012; 46: 865-870.
13. Tseng T-C, Liu C-J, Yang H-C et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012; 55: 68-76.
14. Yeh C-T, Hsu C-W, Chen Y-C, Liaw Y-F. Withdrawal of lamivudine in hbeag-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol 2009; 45: 114-118.
15. Wang L, Liu F, Liu YD et al. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepatitis 2010; 17: 298-304.
16. Pan X, Zhang K, Yang X et al. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One 2013; 8: e68568.
17. Li C, Ji H, Cai Y et al. Serum interleukin-37 concentrations and hbeag seroconversion in chronic HBV patients during telbivudine treatment. J Interferon Cytokine Res 2013; 33: 612-618.
18. Wang GQ, Ding YP, Dong YH. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat 2013; 20 (Suppl 1): 9-17.
19. Ma H, Zhang HH, Wei L. Frequency of t-cell foxp3(+) treg and cd4(+)/cd8(+) pd-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon. Chin Med J (Engl) 2013; 126: 267-273.
20. Wang S, Huang D, Sun S, Ma W, Zhen Q. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa. Virol J 2011; 8: 28.
21. Yan ZH, Fan Y, Wang XH, Mao Q, Deng GH, Wang YM. Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis. World J Gastroenterol 2012; 18: 3119-3128.
22. Lampertico P, Vigano M, Cheroni C et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-896.
23. Wu JF, Chen CH, Ni YH et al. Toll-like receptor and hepatitis B virus clearance in chronic infected patients: a long-term prospective cohort study in taiwan. J Infect Dis 2012; 206: 662-668.
24. Jin YJ, Kim KM, Yoo DJ et al. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J 2012; 9: 239.